Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 255,340 common shares of the Company (the "Options") with effective grant dates of April 27, 2026, May 4, 2026 and May 11, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.

The Options were granted as a material inducement to each employee’s employment and were approved by Definium's Compensation Committee on April 28, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside Definium's equity incentive plans.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260511638193/en/

Investors:
Gitanjali Jain
VP, Head of Investor Relations
[email protected]

Media:
[email protected]

Source: Definium Therapeutics, Inc.

You May Also Be Interested In

• BlackRock ESG Capital Allocation Term Trust (ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting
• SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
• KBRA Assigns Preliminary Ratings to Aspire Mortgage Trust 2026-3 (SPIRE 2026-3)